Anixa Biosciences (ANIX) Stock: Buy, Sell, or Hold?
ANIX - Anixa Biosciences, Inc.
$2.95
0.18 (6.50%)
▲
5d:
+6.12%
30d:
-5.75%
90d:
-3.28%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Sep 09, 2026
0d
Get Alerted When ANIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ANIX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ANIX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ANIX is currently trading at $2.95, which is considered fair relative to its 30-day fair value range of $2.67 to $3.31.
Technical Outlook: Technically, ANIX is in a uptrend. The price is approaching resistance at $2.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.5% recently.
Market Sentiment: ANIX scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (24th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.75 (+230.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ANIX is in a uptrend. The price is approaching resistance at $2.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.5% recently.
Market Sentiment: ANIX scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (24th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.75 (+230.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.67 -
$3.31
Company Quality Score
61/100
(BUY)
Options IV Signal
24th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
93.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 24th percentile)
- BULLISH: Strong technical setup (73/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.5%)
- BULLISH: Trading 230.5% below Wall St target ($9.75)
- CAUTION: Bottoming setup, but lagging the sector by 20% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$2.67 -
$3.31
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.55
(18.5%)
Support & Resistance Levels
Support Level
$2.62
Resistance Level
$2.95
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.52
Wall Street Target
$9.75
(+230.5%)
Share & Embed Analysis
Last updated: October 02, 2026 6:06 PM ET
Data refreshes hourly during market hours. Next update: 7:06 PM
Data refreshes hourly during market hours. Next update: 7:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$21 | 50 HOLD |
